Drug Trial Radar · NCT07938814
A First-in-human (FIH), Open-label, and Multi-center Study of CS5006 in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
310
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Jul 2029
Study completion Jul 2029
Sponsor
- Lead sponsor
- CStone PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS5006 in participants with advanced solid tumors. The study comprises of a Phase I dose escalation and Phase II dose expansion.
Conditions
- Advanced Solid Tumors
Interventions
CS5006Drug
CS5006 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).
Primary outcomes
What the sponsor says the trial is designed to measure.
- [Dose Escalation] Maximum tolerated dose (MTD) of CS5006Time frame: Cycle 1 (Up to 21 Days)
- [Dose Escalation] Tentative recommended Phase II dose (RP2D) of CS5006Time frame: Up to approximately 2 years
- [Dose Escalation] The incidence and severity of adverse events (AEs)Time frame: Up to approximately 2 years
- [Dose Expansion] Objective response rate (ORR) evaluated by investigators per RECIST v1.1Time frame: Up to approximately 2 years
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Macquarie University
North Ryde, New South Wales, Australia
Scientia Clinical Research Ltd
Randwick, New South Wales, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.